ATE342728T1 - Zubereitung zur behandlung von einer neurologischen erkrankung - Google Patents
Zubereitung zur behandlung von einer neurologischen erkrankungInfo
- Publication number
- ATE342728T1 ATE342728T1 AT00918991T AT00918991T ATE342728T1 AT E342728 T1 ATE342728 T1 AT E342728T1 AT 00918991 T AT00918991 T AT 00918991T AT 00918991 T AT00918991 T AT 00918991T AT E342728 T1 ATE342728 T1 AT E342728T1
- Authority
- AT
- Austria
- Prior art keywords
- preparation
- treatment
- neurological disease
- rar22
- agonist
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9907461.9A GB9907461D0 (en) | 1999-03-31 | 1999-03-31 | Neurite regeneration |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE342728T1 true ATE342728T1 (de) | 2006-11-15 |
Family
ID=10850746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00918991T ATE342728T1 (de) | 1999-03-31 | 2000-03-30 | Zubereitung zur behandlung von einer neurologischen erkrankung |
Country Status (11)
Country | Link |
---|---|
US (2) | US20070054961A1 (de) |
EP (2) | EP1180039B1 (de) |
JP (1) | JP2002540164A (de) |
KR (1) | KR20010104401A (de) |
CN (1) | CN100350970C (de) |
AT (1) | ATE342728T1 (de) |
AU (1) | AU770394B2 (de) |
CA (1) | CA2369009A1 (de) |
DE (1) | DE60031396T2 (de) |
GB (2) | GB9907461D0 (de) |
WO (1) | WO2000057900A2 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001075135A1 (en) * | 2000-03-30 | 2001-10-11 | Oxford Biomedica (Uk) Limited | Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
GB0103998D0 (en) * | 2001-02-19 | 2001-04-04 | King S College London | Method |
EP1592867B1 (de) | 2003-02-11 | 2016-11-23 | Statoil ASA | Effizientes kraftwerk mit kombiniertem zyklus mit co2-auffang und brennkammeranordnung mit getrennten strömungen |
EP2931899A1 (de) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Funktionale genomik unter verwendung von crispr-cas systemen, zusammensetzungen, verfahren, knockout-bibliotheken und anwendungen davon |
MX2015007550A (es) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas. |
SG11201510286QA (en) | 2013-06-17 | 2016-01-28 | Broad Inst Inc | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components |
DK3011032T3 (da) | 2013-06-17 | 2020-01-20 | Broad Inst Inc | Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til målretning mod og modellering af sygdomme og forstyrrelser i postmitotiske celler |
DK3011031T3 (da) | 2013-06-17 | 2020-12-21 | Broad Inst Inc | Fremføring og anvendelse af crispr-cas-systemerne, vektorer og sammensætninger til levermålretning og -terapi |
JP6625055B2 (ja) | 2013-12-12 | 2020-01-08 | ザ・ブロード・インスティテュート・インコーポレイテッド | 組成物、及びヌクレオチドリピート障害におけるcrispr−cas系の使用方法 |
DK3079725T3 (da) | 2013-12-12 | 2020-01-20 | Broad Inst Inc | Administration, brug og terapeutiske anvendelser af crispr-cas-systemerne og sammensætninger til genomredigering |
CN111269902A (zh) | 2013-12-12 | 2020-06-12 | 布罗德研究所有限公司 | Crispr-cas***和组合物的递送及用途 |
EP4219699A1 (de) | 2013-12-12 | 2023-08-02 | The Broad Institute, Inc. | Konstruktion von systemen, verfahren und optimierten führungszusammensetzungen mit neuen architekturen zur sequenzmanipulation |
WO2015089486A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems |
EP3686279B1 (de) | 2014-08-17 | 2023-01-04 | The Broad Institute, Inc. | Genombearbeitung mit cas9-nickasen |
WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
WO2016049258A2 (en) | 2014-09-25 | 2016-03-31 | The Broad Institute Inc. | Functional screening with optimized functional crispr-cas systems |
WO2016094880A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
WO2016094867A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Protected guide rnas (pgrnas) |
EP3230452A1 (de) | 2014-12-12 | 2017-10-18 | The Broad Institute Inc. | Totführungen für crispr-transkriptionsfaktoren |
WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
JP6596090B2 (ja) | 2014-12-17 | 2019-10-23 | キングス カレッジ ロンドン | レチノイン酸受容体ベータ(RARβ)アゴニストとしてのビシクロヘテロアリール−ヘテロアリール−安息香酸化合物 |
WO2016100974A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute Inc. | Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing |
WO2016106236A1 (en) | 2014-12-23 | 2016-06-30 | The Broad Institute Inc. | Rna-targeting system |
CA2970370A1 (en) | 2014-12-24 | 2016-06-30 | Massachusetts Institute Of Technology | Crispr having or associated with destabilization domains |
EP3307781B8 (de) | 2015-06-10 | 2020-12-02 | The Broad Institute, Inc. | Antikörper, verbindungen und tests zur identifizierung und behandlung von kachexie oder präkachexie |
FI3430134T3 (fi) | 2015-06-18 | 2023-01-13 | Uusia CRISPR-entsyymejä ja järjestelmiä | |
WO2016205749A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
WO2016205613A1 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Crispr enzyme mutations reducing off-target effects |
WO2016205745A2 (en) | 2015-06-18 | 2016-12-22 | The Broad Institute Inc. | Cell sorting |
US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
EP3337908A4 (de) | 2015-08-18 | 2019-01-23 | The Broad Institute, Inc. | Verfahren und zusammensetzungen zur veränderung der funktion und struktur von chromatinschleifen und/oder -domänen |
US20190255107A1 (en) | 2015-10-09 | 2019-08-22 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
CN109153980B (zh) | 2015-10-22 | 2023-04-14 | 布罗德研究所有限公司 | Vi-b型crispr酶和*** |
US11492670B2 (en) | 2015-10-27 | 2022-11-08 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
WO2017075465A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3 |
WO2017075451A1 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1 |
WO2017075478A2 (en) | 2015-10-28 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures |
WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
SG10202010311SA (en) | 2016-04-19 | 2020-11-27 | Broad Inst Inc | Novel Crispr Enzymes and Systems |
US20200263190A1 (en) | 2016-04-19 | 2020-08-20 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
CA3026112A1 (en) | 2016-04-19 | 2017-10-26 | The Broad Institute, Inc. | Cpf1 complexes with reduced indel activity |
US11788083B2 (en) | 2016-06-17 | 2023-10-17 | The Broad Institute, Inc. | Type VI CRISPR orthologs and systems |
GB201610867D0 (en) | 2016-06-22 | 2016-08-03 | King's College London | Crystalline forms of a therapeutic compound and processes for their preparation |
US20210222164A1 (en) | 2016-06-29 | 2021-07-22 | The Broad Institute, Inc. | Crispr-cas systems having destabilization domain |
US11352647B2 (en) | 2016-08-17 | 2022-06-07 | The Broad Institute, Inc. | Crispr enzymes and systems |
US20200283743A1 (en) | 2016-08-17 | 2020-09-10 | The Broad Institute, Inc. | Novel crispr enzymes and systems |
US20190262399A1 (en) | 2016-09-07 | 2019-08-29 | The Broad Institute, Inc. | Compositions and methods for evaluating and modulating immune responses |
US20200016202A1 (en) | 2016-10-07 | 2020-01-16 | The Brigham And Women's Hospital, Inc. | Modulation of novel immune checkpoint targets |
ES2950676T3 (es) | 2017-01-30 | 2023-10-11 | Kws Saat Se & Co Kgaa | Reparación de enlace de plantillas a endonucleasas para modificación de genes |
US11739308B2 (en) | 2017-03-15 | 2023-08-29 | The Broad Institute, Inc. | Cas13b orthologues CRISPR enzymes and systems |
KR20200006054A (ko) | 2017-04-12 | 2020-01-17 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신규 타입 vi crispr 오르소로그 및 시스템 |
WO2018191750A2 (en) | 2017-04-14 | 2018-10-18 | The Broad Institute Inc. | Novel delivery of large payloads |
US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
CN111511388A (zh) | 2017-09-21 | 2020-08-07 | 博德研究所 | 用于靶向核酸编辑的***、方法和组合物 |
WO2019071054A1 (en) | 2017-10-04 | 2019-04-11 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING THE FUNCTION AND STRUCTURE OF BUCKLES AND / OR CHROMATIN DOMAINS |
US11547614B2 (en) | 2017-10-31 | 2023-01-10 | The Broad Institute, Inc. | Methods and compositions for studying cell evolution |
WO2019094983A1 (en) | 2017-11-13 | 2019-05-16 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
US10968257B2 (en) | 2018-04-03 | 2021-04-06 | The Broad Institute, Inc. | Target recognition motifs and uses thereof |
EP3833761A1 (de) | 2018-08-07 | 2021-06-16 | The Broad Institute, Inc. | Neuartige cas12b-enzyme und systeme |
US20210317429A1 (en) | 2018-08-20 | 2021-10-14 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
EP3898958A1 (de) | 2018-12-17 | 2021-10-27 | The Broad Institute, Inc. | Crispr-assoziierte transposase-systeme und verfahren zu deren verwendung |
US20220177863A1 (en) | 2019-03-18 | 2022-06-09 | The Broad Institute, Inc. | Type vii crispr proteins and systems |
US20220220469A1 (en) | 2019-05-20 | 2022-07-14 | The Broad Institute, Inc. | Non-class i multi-component nucleic acid targeting systems |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4657857A (en) | 1982-05-19 | 1987-04-14 | Internationale Octrooi Maatschappij "Octropa" B.V. | Yeast of the genus kluyveromyces modified for the expression of preprothaumatin or its various allelic and modified forms or their maturation forms, and the proteins obtained by that expression |
NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
GR82200B (de) | 1983-07-06 | 1984-12-13 | Gist Brocades Nv | |
US4885249A (en) | 1984-12-05 | 1989-12-05 | Allelix, Inc. | Aspergillus niger transformation system |
AU606033B2 (en) | 1985-04-15 | 1991-01-31 | Dsm Ip Assets B.V. | Promotors of filamentous fungi and use thereof |
NO872932L (no) | 1986-07-18 | 1988-01-19 | Gist Brocades Nv | Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika. |
US4808630A (en) * | 1987-01-16 | 1989-02-28 | United States Of America | Method of treating psychotic illnesses |
HU201870B (en) * | 1987-01-16 | 1991-01-28 | Us Health | Process for producing pharmaceutical compositions containing isoretinoin as active component |
ATE97446T1 (de) | 1987-07-28 | 1993-12-15 | Gist Brocades Nv | Kluyveromyces als wirtsstamm. |
KR100225087B1 (ko) | 1990-03-23 | 1999-10-15 | 한스 발터라벤 | 피타아제의 식물내 발현 |
CA2211142A1 (en) * | 1995-01-23 | 1996-08-01 | Ligand Pharmaceuticals Incorporated | Human retinoid x receptor - gamma (hrxr-gamma) |
IT1276459B1 (it) * | 1995-06-30 | 1997-10-31 | Khodor Ammar | Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la |
FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
US5965606A (en) * | 1995-12-29 | 1999-10-12 | Allergan Sales, Inc. | Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity |
AU6897498A (en) | 1997-04-25 | 1998-11-24 | American Home Products Corporation | Human neuronal cell line |
CA2307826A1 (en) * | 1997-10-27 | 1999-05-06 | Creative Biomolecules, Inc. | Enhancement of morphogen activity |
-
1999
- 1999-03-31 GB GBGB9907461.9A patent/GB9907461D0/en not_active Ceased
-
2000
- 2000-03-30 GB GB0123381A patent/GB2365772A/en not_active Withdrawn
- 2000-03-30 AT AT00918991T patent/ATE342728T1/de not_active IP Right Cessation
- 2000-03-30 AU AU39755/00A patent/AU770394B2/en not_active Ceased
- 2000-03-30 EP EP00918991A patent/EP1180039B1/de not_active Expired - Lifetime
- 2000-03-30 EP EP06076367A patent/EP1762243A1/de not_active Withdrawn
- 2000-03-30 CN CNB008080887A patent/CN100350970C/zh not_active Expired - Fee Related
- 2000-03-30 KR KR1020017012263A patent/KR20010104401A/ko not_active Application Discontinuation
- 2000-03-30 DE DE60031396T patent/DE60031396T2/de not_active Expired - Fee Related
- 2000-03-30 JP JP2000607650A patent/JP2002540164A/ja active Pending
- 2000-03-30 CA CA002369009A patent/CA2369009A1/en not_active Abandoned
- 2000-03-30 WO PCT/GB2000/001211 patent/WO2000057900A2/en active IP Right Grant
-
2006
- 2006-09-25 US US11/526,458 patent/US20070054961A1/en not_active Abandoned
-
2009
- 2009-09-30 US US12/570,659 patent/US20100317109A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1180039A2 (de) | 2002-02-20 |
JP2002540164A (ja) | 2002-11-26 |
DE60031396T2 (de) | 2007-08-30 |
WO2000057900A2 (en) | 2000-10-05 |
US20070054961A1 (en) | 2007-03-08 |
KR20010104401A (ko) | 2001-11-26 |
AU770394B2 (en) | 2004-02-19 |
CN100350970C (zh) | 2007-11-28 |
AU3975500A (en) | 2000-10-16 |
WO2000057900A3 (en) | 2001-02-15 |
CN1355706A (zh) | 2002-06-26 |
GB2365772A (en) | 2002-02-27 |
CA2369009A1 (en) | 2000-10-05 |
EP1180039B1 (de) | 2006-10-18 |
DE60031396D1 (de) | 2006-11-30 |
GB0123381D0 (en) | 2001-11-21 |
US20100317109A1 (en) | 2010-12-16 |
EP1762243A1 (de) | 2007-03-14 |
GB9907461D0 (en) | 1999-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60031396D1 (de) | Zubereitung zur behandlung von einer neurologischen erkrankung | |
DE69829921D1 (de) | Vorrichtung zur Behandlung von Körpergewebe | |
DE69903543T2 (de) | Formulierungen zur behandlung von magen-speiseröhren reflux | |
ATE248599T1 (de) | Verwendung von xenon zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von neurovergiftungen | |
DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATE308997T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
DE69918687D1 (de) | 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen | |
DE69939058D1 (de) | Vorrichtung zur behandlung von peripheren gefässerkrankungen | |
ATE447947T1 (de) | Pharmazeutische zubereitungen zur behandlung von insulinresitenz | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
ATA76995A (de) | Stabiles präparat zur behandlung von blutgerinnungsstörungen | |
DE60028863D1 (de) | Elektrochirurgisches Handstück zur Behandlung von Gewebe | |
ATE292134T1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
DE69824576D1 (de) | Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen | |
DE50013843D1 (de) | Arzneimittel zur behandlung von darmerkrankungen | |
DE29901517U1 (de) | Vorrichtung zur abtragenden Behandlung von Hornhaut, insbesondere bei der Fußpflege | |
DE69910202D1 (de) | EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden | |
DE69420229T2 (de) | Pharmazeutische Zusammensetzung zur Behandlung von AIDS | |
DE69822297D1 (de) | Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten | |
DE60001255D1 (de) | Zusammensetzung zur Behandlung von Polyesterfaser | |
ATE299371T1 (de) | Antikonvulsiva zur behandlung von autismus | |
DE69913380D1 (de) | Zusammensetzung zur behandlung von periodontalen erkrankungen | |
ATE330938T1 (de) | Disulfid-derivate verwendbar zur behandlung von allergischen erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1180039 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |